CDER Hit Most Review Targets in 2020 Despite Pandemic Obstacles

Despite the COVID-19 pandemic making manufacturing site inspections difficult in 2020, the FDA’s Center for Drug Evaluation and Research (CDER) met most of its drug and biologic review goals last year, but — as it warned it would — the agency struggled to meet its inspection goals.
Source: Drug GMP Report